Editas, one of the oldest CRISPR-focused biotechs, is pivoting again — to a sickle cell treatment that requires editing a ...

Editas Medicine is pushing its in vivo gene therapy strategy to the top of its agenda, boasting proof-of-concept data and ...

AvenCell Therapeutics announced that it raised $115 million in a Series B round. The company is developing CAR-T therapies ...

Chardan analyst Geulah Livshits lowered the firm’s price target on Editas Medicine (EDIT) to $12 from $20 and keeps a Buy rating on the shares. The company presented proof-of-concept preclinical in ...

Baird lowered the firm’s price target on Editas Medicine (EDIT) to $10 from $18 and keeps an Outperform rating on the shares. The firm ...

Editas is partnering its CRISPR platform with Genevant’s LNP technology to develop novel gene editing medicines in a deal ...

The gene editing company will focus on “in vivo” medicines, while seeking to license out or find a development partner for its clinical-stage treatment reni-cel.

Editas Medicine, Inc. EDIT announced that it has entered into a collaboration and nonexclusive license agreement with ...

Editas Medicine, Inc. ( NASDAQ: EDIT) Strategic Update Conference Call October 22, 2024 8:00 AM ET ...

On Thursday, Editas Medicine Inc (EDIT) stock saw a decline, ending the day at $3.31 which represents a decrease of $-0.14 or -4.06% from the prior close of $3.45. The stock opened at $3.46 and ...

Given the large stake in the stock by institutions, Editas Medicine's stock price might be vulnerable to their trading ...

On Friday, Editas Medicine Inc (EDIT) stock saw a modest uptick, ending the day at $3.36 which represents a slight increase of $0.05 or 1.51% from the prior close of $3.31. The stock opened at $3.32 ...